CPC A61K 9/143 (2013.01) [A61K 9/146 (2013.01); A61K 31/519 (2013.01); A61K 45/06 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); C07K 16/2827 (2013.01); A61K 9/0019 (2013.01); B82Y 5/00 (2013.01)] | 20 Claims |
1. A therapeutic construct comprising:
a mesoporous silica nanoparticle (MSNP) comprising platform loaded with:
a small molecule mitotic kinase inhibitor in an amount 0.01% to 5% by weight of the therapeutic construct, or a mitotic kinase-specific siRNA; and
a Programmed Death-Ligand 1 (PD-L1) antibody conjugated onto the MSNP platform.
|